This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Pulzium - Intravenous
Drug Names(s): Tedisamil - Intravenous, KC-8857
Description: Pulzium blocks potassium channels in conducting cells of the heart, specifically the rapid potassium current, the transient outward pottasium current, and the ATP sensitive potassium current (which operates only when there are low levels of oxygen).
Intravenous pulzium is being developed to convert atrial fibrillation/flutter to normal rhythm.
Deal Structure: Pulzium was originally developed by Solvay.
In September 2009, Solvay announced that its Board of Directors has decided to sell its entire pharmaceutical business to Abbott for a total Entreprise Value of about EUR 5.2 billion. This includes a purchase price of EUR 4.5 billion in cash and additional potential payments of up to EUR 300 million if certain milestones are met between 2011 and 2013. The acquisition was completed in February 2010.
Pulzium - Intravenous News
Additional information available to subscribers only: